HIV-1 Drug Resistance in ART-Naïve Individuals in Myanmar

References

• World Health Organization [homepage on the Internet]. HIV/AIDS data and statistics; 2019 Available from: https://www.who.int/hiv/data/en/. Accessed 122, 2019.
   Google Scholar
• Trickey A, May MT, Vehreschild JJ, et al. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;4(8):e349–e356. doi:10.1016/S2352-3018(17)30066-828501495
   PubMed Web of Science ®Google Scholar
• Eaton JW, Johnson LF, Salomon JA, et al. HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med. 2012;9(7):e1001245. doi:10.1371/journal.pmed.100124522802730
   PubMed Web of Science ®Google Scholar
• Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med. 2001;135(1):17–26. doi:10.7326/0003-4819-135-1-200107030-0000511434728
   PubMed Web of Science ®Google Scholar
• Paraskevis D, Kostaki E, Magiorkinis G, et al. Prevalence of drug resistance among HIV-1 treatment-naive patients in Greece during 2003–2015: transmitted drug resistance is due to onward transmissions. Infect Genet Evol. 2017;54:183–191. doi:10.1016/j.meegid.2017.07.00328688977
   PubMed Web of Science ®Google Scholar
• Stadeli KM, Richman DD. Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther. 2013;18(1):115–123. doi:10.3851/IMP243723052978
   PubMed Web of Science ®Google Scholar
• Socias ME, Nosova E, Kerr T, et al. Patterns of transmitted drug resistance and virological response to first-line antiretroviral treatment among Human Immunodeficiency virus-infected people who use illicit drugs in a Canadian setting. Clin Infect Dis. 2017;65(5):796–802. doi:10.1093/cid/cix42828482025
   PubMed Web of Science ®Google Scholar
• Stekler JD, Milne R, Payant R, et al. Transmission of HIV-1 drug resistance mutations within partner-pairs: a cross-sectional study of a primary HIV infection cohort. PLoS Med. 2018;15(3):e1002537. doi:10.1371/journal.pmed.100253729584723
   PubMed Web of Science ®Google Scholar
• Clutter DS, Jordan MR, Bertagnolio S, Shafer RW. HIV-1 drug resistance and resistance testing. Infect Genet Evol. 2016;46:292–307. doi:10.1016/j.meegid.2016.08.03127587334
   PubMed Web of Science ®Google Scholar
• Smith DM, May SJ, Tweeten S, et al. A public health model for the molecular surveillance of HIV transmission in San Diego, California. AIDS. 2009;23(2):225–232. doi:10.1097/QAD.0b013e32831d2a8119098493
   PubMed Web of Science ®Google Scholar
• Zuo L, Liu K, Liu H, et al. Trend of HIV-1 drug resistance in China: a systematic review and meta-analysis of data accumulated over 17 years (2001–2017). EClinicalMedicine. 2020;18:100238. doi:10.1016/j.eclinm.2019.10023831922125
   PubMedGoogle Scholar
• Petersen A, Cowan SA, Nielsen J, Fischer TK, Fonager J. Characterisation of HIV-1 transmission clusters and drug-resistant mutations in Denmark, 2004 to 2016. Euro Surveill. 2018;23(44). doi:10.2807/1560-7917.ES.2018.23.44.1700633
   Google Scholar
• Stecher M, Chaillon A, Eis-Hubinger AM, et al. Pretreatment human immunodeficiency virus type 1 (HIV-1) drug resistance in transmission clusters of the Cologne-Bonn region, Germany. Clin Microbiol Infect. 2019;25(2):253. doi:10.1016/j.cmi.2018.09.02530315957
   PubMed Web of Science ®Google Scholar
• Drescher SM, von Wyl V, Yang WL, et al. Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study. Clin Infect Dis. 2014;58(2):285–294. doi:10.1093/cid/cit69424145874
   PubMed Web of Science ®Google Scholar
• Mbisa JL, Fearnhill E, Dunn DT, Pillay D, Asboe D, Cane PA. Evidence of self-sustaining drug resistant HIV-1 lineages among untreated patients in the United Kingdom. Clin Infect Dis. 2015;61(5):829–836. doi:10.1093/cid/civ39325991470
   PubMed Web of Science ®Google Scholar
• Fabeni L, Alteri C, Di Carlo D, et al. Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000–14. J Antimicrob Chemother. 2017;72(10):2837–2845. doi:10.1093/jac/dkx23129091206
   PubMed Web of Science ®Google Scholar
• Vega Y, Delgado E, Fernandez-Garcia A, et al. Epidemiological surveillance of HIV-1 transmitted drug resistance in Spain in 2004–2012: relevance of transmission clusters in the propagation of resistance mutations. PLoS One. 2015;10(5):e0125699. doi:10.1371/journal.pone.012569926010948
   PubMed Web of Science ®Google Scholar
• Jair K, McCann CD, Reed H, et al. Validation of publicly-available software used in analyzing NGS data for HIV-1 drug resistance mutations and transmission networks in a Washington, DC, Cohort. PLoS One. 2019;14(4):e0214820. doi:10.1371/journal.pone.021482030964884
   PubMed Web of Science ®Google Scholar
• Brenner BG, Roger M, Moisi DD, et al. Transmission networks of drug resistance acquired in primary/early stage HIV infection. AIDS. 2008;22(18):2509–2515. doi:10.1097/QAD.0b013e3283121c9019005274
   PubMed Web of Science ®Google Scholar
• The World Bank [homepage on the Internet]. The World Bank in Myanmar; 2019 Available from: https://www.worldbank.org/en/country/myanmar/overview. Accessed 122, 2019.
   Google Scholar
• Kusagawa S, Sato H, Watanabe S, et al. Genetic and serologic characterization of HIV type 1 prevailing in Myanmar (Burma). AIDS Res Hum Retroviruses. 1998;14(15):1379–1385. doi:10.1089/aid.1998.14.13799788679
   PubMed Web of Science ®Google Scholar
• Htoon MT, Lwin HH, San KO, Zan E, Thwe M. HIV/AIDS in Myanmar. AIDS. 1994;8(Suppl 2):S105–S109.7857552
   PubMed Web of Science ®Google Scholar
• The Joint United Nations Programme on HIV/AIDS [homepage on the Internet]. HIV and AIDS estimates; 2019 Available from: http://aidsinfo.unaids.org/. Accessed 122, 2019.
   Google Scholar
• Kyaw NT, Harries AD, Kumar AM, et al. High rate of virological failure and low rate of switching to second-line treatment among adolescents and adults living with HIV on first-line ART in Myanmar, 2005–2015. PLoS One. 2017;12(2):e0171780. doi:10.1371/journal.pone.017178028182786
   PubMed Web of Science ®Google Scholar
• Rhee SY, Blanco JL, Jordan MR, et al. Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis. PLoS Med. 2015;12(4):e1001810. doi:10.1371/journal.pmed.100181025849352
   PubMed Web of Science ®Google Scholar
• Zazzi M, Hu H, Prosperi M. The global burden of HIV-1 drug resistance in the past 20 years. PeerJ. 2018;6:e4848. doi:10.7717/peerj.484829844989
   PubMed Web of Science ®Google Scholar
• Zhou YH, Liu FL, Yao ZH, et al. Comparison of HIV-, HBV-, HCV- and co-infection prevalence between Chinese and Burmese intravenous drug users of the China-Myanmar border region. PLoS One. 2011;6(1):e16349. doi:10.1371/journal.pone.001634921283696
   PubMed Web of Science ®Google Scholar
• Pang W, Zhang C, Duo L, et al. Extensive and complex HIV-1 recombination between B’, C and CRF01_AE among IDUs in south-east Asia. AIDS. 2012;26(9):1121–1129. doi:10.1097/QAD.0b013e3283522c9722333750
   PubMed Web of Science ®Google Scholar
• Chen X, Zhou YH, Ye M, et al. Burmese injecting drug users in Yunnan play a pivotal role in the cross-border transmission of HIV-1 in the China-Myanmar border region. Virulence. 2018;9(1):1195–1204. doi:10.1080/21505594.2018.149677730001176
   PubMed Web of Science ®Google Scholar
• Zhou YH, Liang YB, Pang W, et al. Diverse forms of HIV-1 among Burmese long-distance truck drivers imply their contribution to HIV-1 cross-border transmission. BMC Infect Dis. 2014;14(1):463. doi:10.1186/1471-2334-14-46325158600
   PubMed Web of Science ®Google Scholar
• Wan Z, Chen Q, Chen X, et al. HCV diversity among Chinese and Burmese IDUs in Dehong, Yunnan, China. PLoS One. 2016;11(9):e0163062. doi:10.1371/journal.pone.016306227657722
   PubMed Web of Science ®Google Scholar
• Xuan Q, Liang S, Qin W, et al. High prevalence of HIV-1 transmitted drug resistance among therapy-naive Burmese entering travelers at Dehong ports in Yunnan, China. BMC Infect Dis. 2018;18(1):211. doi:10.1186/s12879-018-3130-929739342
   PubMed Web of Science ®Google Scholar
• Chen X, Ye M, Duo L, et al. First description of two new HIV-1 recombinant forms CRF82_cpx and CRF83_cpx among drug users in Northern Myanmar. Virulence. 2017;8(5):497–503. doi:10.1080/21505594.2016.122672227574950
   PubMed Web of Science ®Google Scholar
• Chen X, Ye M, Pang W, Smith DM, Zhang C, Zheng YT. First appearance of HIV-1 CRF07_BC and CRF08_BC outside China. AIDS Res Hum Retroviruses. 2017;33(1):74–76. doi:10.1089/aid.2016.016927392826
   PubMed Web of Science ®Google Scholar
• Kaye M, Chibo D, Birch C. Phylogenetic investigation of transmission pathways of drug-resistant HIV-1 utilizing pol sequences derived from resistance genotyping. J Acquir Immune Defic Syndr. 2008;49(1):9–16. doi:10.1097/QAI.0b013e318180c8af18667928
   PubMed Web of Science ®Google Scholar
• Chen M, Ma Y, Chen H, et al. HIV-1 genetic transmission networks among men who have sex with men in Kunming, China. PLoS One. 2018;13(4):e0196548. doi:10.1371/journal.pone.019654829698467
   PubMed Web of Science ®Google Scholar
• Chen M, Ma Y, Duan S, et al. Genetic diversity and drug resistance among newly diagnosed and antiretroviral treatment-naive HIV-infected individuals in western Yunnan: a hot area of viral recombination in China. BMC Infect Dis. 2012;12(1):382. doi:10.1186/1471-2334-12-38223270497
   PubMed Web of Science ®Google Scholar
• Wei H, Xing H, Hsi JH, et al. The sexually driven epidemic in youths in China’s southwestern border region was caused by dynamic emerging multiple recombinant HIV-1 strains. Sci Rep. 2015;5(1):11323. doi:10.1038/srep1132326133091
   PubMed Web of Science ®Google Scholar
• United States Agency for International Development [homepage on the Internet]. Guidelines for the clinical management of HIV infection in Myanmar; 2017 Available from: https://aidsfree.usaid.gov/sites/default/files/mmr_hiv_guidelines_2017.pdf. Accessed 122, 2019.
   Google Scholar
• World Health Organization [homepage on the Internet]. HIV drug resistance report 2017; 2017 Available from: https://www.who.int/hiv/pub/drugresistance/hivdr-report-2017/en/. Accessed 122, 2019.
   Google Scholar
• Yao ST, Chen M, Li YL, et al. HIV drug resistance analysis among Burmese with antiretroviral treatment in Dehong Prefecture, Yunnan Province. Zhonghua Yu Fang Yi Xue Za Zhi. 2016;50(11):1008–1010. doi:10.3760/cma.j.issn.0253-9624.2016.11.01627903365
   PubMedGoogle Scholar
• Sanguansittianant S, Nooroon N, Phaengchomduan P, Ammaranond P. Trends in prevalence of HIV-1 drug resistance in Thailand 2009–2010. J Clin Lab Anal. 2013;27(5):346–353. doi:10.1002/jcla.2160924038219
   PubMed Web of Science ®Google Scholar
• Sharma AL, Singh TR, Singh LS. Antiretroviral resistance, genotypic characterization and origin of human immunodeficiency virus among the infected wives of intravenous drug users in Manipur. Sci Rep. 2018;8(1):15183. doi:10.1038/s41598-018-33636-z30315192
   PubMed Web of Science ®Google Scholar
• Liu J, Jia Y, Xu Q, Zheng YT, Zhang C. Phylodynamics of HIV-1 unique recombinant forms in China-Myanmar border: implication for HIV-1 transmission to Myanmar from Dehong, China. Infect Genet Evol. 2012;12(8):1944–1948. doi:10.1016/j.meegid.2012.08.00122917657
   PubMed Web of Science ®Google Scholar
• Chen X, Duo L, Ye M, Zhang C, Zheng YT. Non-Chinese immigrants: challenge faced by Yunnan of China to achieve the 90–90–90 goals. Virol Sin. 2018;33(3):291–293. doi:10.1007/s12250-018-0038-x29931513
   PubMed Web of Science ®Google Scholar
• Liu Y, Li H, Wang X, et al. Natural presence of V179E and rising prevalence of E138G in HIV-1 reverse transcriptase in CRF55_01B viruses. Infect Genet Evol. 2019;77:104098. doi:10.1016/j.meegid.2019.10409831678241
   PubMed Web of Science ®Google Scholar
• Sluis-Cremer N, Jordan MR, Huber K, et al. E138A in HIV-1 reverse transcriptase is more common in subtype C than B: implications for rilpivirine use in resource-limited settings. Antiviral Res. 2014;107:31–34. doi:10.1016/j.antiviral.2014.04.00124746459
   PubMed Web of Science ®Google Scholar
• Smit E, White E, Clark D, et al. An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs. J Antimicrob Chemother. 2017;72(7):2075–2082. doi:10.1093/jac/dkx09128379449
   PubMed Web of Science ®Google Scholar
• Mackie NE, Dunn DT, Dolling D, et al. The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults. AIDS. 2013;27(14):2245–2253. doi:10.1097/QAD.0b013e328363617924157905
   PubMed Web of Science ®Google Scholar